Get the Stockscreener App
0.6765
2.71%
0.0165
Plus Therapeutics Inc stock is traded at $0.6765, with a volume of 1.40M.
It is up +2.71% in the last 24 hours and down -9.61% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.66
Open:
$0.6734
24h Volume:
1.40M
Relative Volume:
0.09
Market Cap:
$10.54M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2674
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+9.29%
1M Performance:
-9.61%
6M Performance:
-47.45%
1Y Performance:
-68.62%
1-Day Range:
$0.6209
$0.7184
1-Week Range:
$0.4924
$0.7184
52-Week Range:
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.6765 | 10.54M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.04 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.96 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.51 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.66 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.24 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World
Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus
PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com
Form 8-KCurrent report - ADVFN
Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News
Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com
Plus Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - The Houston 100
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Plus Therapeutics adds Kyle Guse to its Board of Directors By Investing.com - Investing.com South Africa
Plus Therapeutics Inc (PSTV) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Plus Therapeutics adds Kyle Guse to its Board of Directors - Investing.com
Plus Therapeutics (PSTV) Welcomes Kyle Guse to Board as Audit Ch - GuruFocus
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors - marketscreener.com
Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World
Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World
Plus Therapeutics Appoints Kyle Guse to Board - MSN
Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada
Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus
Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus
Plus Therapeutics reports progress in CNS cancer treatment - Investing.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire
New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan
Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus
Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister
Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks
Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com
PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):